Want to see IN:UNICHEMLAB full AI Analyst Report?
UNICHEMLAB Stock Chart & Stats
₹443.05
-₹12.85(-1.76%)
At close: 4:00 PM EST
₹443.05
-₹12.85(-1.76%)
Day’s Range― - ―
52-Week Range₹280.00 - ₹685.95
Previous CloseN/A
Volume14.19K
Average Volume (3M)14.55K
Market Cap
₹38.47B
Enterprise Value₹22.74K
Total Cash (Recent Filing)₹2.89B
Total Debt (Recent Filing)₹0.00
Price to Earnings (P/E)12.3
Beta1.28
Next Earnings
Nov 04, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield1.34%
Share Statistics
EPS (TTM)43.29
Shares Outstanding70,405,754
10 Day Avg. Volume26,201
30 Day Avg. Volume14,549
Financial Highlights & Ratios
PEG Ratio0.10
Price to Book (P/B)0.76
Price to Sales (P/S)0.94
P/FCF Ratio-14.89
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Conservative Balance SheetConservative leverage and a substantial equity base provide financial resilience and reduce balance-sheet pressure. This gives Unichem greater flexibility to sustain operations, absorb earnings volatility, and pursue product or market initiatives without depending heavily on debt funding.
Long-term Revenue ExpansionThe multi-year revenue expansion indicates that Unichem has demonstrated the ability to grow its commercial base across pharmaceutical formulations and markets. Broader product and geographic reach can support recurring demand and create a foundation for future scale, despite recent softness.
Return To ProfitabilityThe return to profitability marks a meaningful improvement in earnings performance after the loss years. A positive net margin provides internal earnings support for operations and investment, while demonstrating that the business can recover financially when revenue and execution conditions improve.
Bears Say
Persistently Weak Cash GenerationPersistent negative operating and free cash flow weakens the quality of reported earnings and can increase reliance on funding flexibility. Continued cash burn may constrain reinvestment, reduce resilience during weaker trading periods, and raise execution risk if operating conditions become less favorable.
Recent Revenue ContractionThe latest revenue decline interrupts the prior expansion trend and indicates that commercial momentum is not consistently sustained. If weakness persists, lower scale could limit operating leverage, reduce the capacity to absorb fixed costs, and make the recent earnings recovery harder to maintain.
Thin And Volatile Operating ProfitabilityA thin operating margin leaves limited protection against changes in revenue or costs, while large gross-margin swings signal an uneven earnings profile. This volatility makes profitability less predictable and could restrict the company’s ability to convert growth into durable operating returns.
Unichem Laboratories Limited News
UNICHEMLAB FAQ
What was Unichem Laboratories Limited’s price range in the past 12 months?
Unichem Laboratories Limited lowest stock price was ₹280.00 and its highest was ₹685.95 in the past 12 months.
What is Unichem Laboratories Limited’s market cap?
Unichem Laboratories Limited’s market cap is ₹38.47B.
When is Unichem Laboratories Limited’s upcoming earnings report date?
Unichem Laboratories Limited’s upcoming earnings report date is Nov 04, 2026 which is in 33 days.
How were Unichem Laboratories Limited’s earnings last quarter?
Unichem Laboratories Limited released its earnings results on Aug 11, 2026. The company reported ₹5.89 earnings per share for the quarter.
Is Unichem Laboratories Limited overvalued?
According to Wall Street analysts Unichem Laboratories Limited’s price is currently Overvalued.
Does Unichem Laboratories Limited pay dividends?
Unichem Laboratories Limited pays a Annually dividend of ₹4 which represents an annual dividend yield of 1.34%. See more information on Unichem Laboratories Limited dividends here
What is Unichem Laboratories Limited’s EPS estimate?
Unichem Laboratories Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Unichem Laboratories Limited have?
Unichem Laboratories Limited has 70,405,754 shares outstanding.
What happened to Unichem Laboratories Limited’s price movement after its last earnings report?
Unichem Laboratories Limited reported an EPS of ₹5.89 in its last earnings report. Following the earnings report the stock price went up 13.062%.
Which hedge fund is a major shareholder of Unichem Laboratories Limited?
Currently, no hedge funds are holding shares in IN:UNICHEMLAB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Unichem Laboratories Limited
Unichem Laboratories Limited is an international pharmaceutical company engaged in the development, manufacturing, and commercialization of a wide array of medicinal products. The firm's portfolio features finished pharmaceutical formulations designed to treat numerous health conditions, including those related to gastroenterology, cardiovascular health, diabetes, mental health, neurological disorders, bacterial and other infectious diseases, and pain relief. Beyond these formulations, Unichem also provides active pharmaceutical ingredients (APIs) and offers contract manufacturing solutions. This enterprise was established in 1944 and operates from its corporate headquarters in Mumbai, India.
Technical Analysis
Gufic Biosciences Limited
―
Hikal Limited
―
Indoco Remedies Limited
―
Morepen Laboratories Limited
―
Windlas Biotech Ltd.
―